Skip to main content

Table 1 The characteristics of included RCTs

From: The effects of vitamin D supplementation on endothelial activation among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Authors (Ref) Publication year Country Intervention/control (sample size) Duration (week) Method of administration/Dosage Patients Weight change/BMI at baseline Intervention/control (age participants)
Arnson at al. [19] 2013 Israel 25/25 5 days Oral/4000 IU 25(OH)-vitamin D/day Patients with acute coronary syndrome NR/NR 61.6 ± 12.7, 59.7 ± 13.4
Witham (a) et al. [17] 2013 Scotland 36/39 6 months Oral/ 100,000 IU vitamin D3 (0, 2 and 4 months) Patients with a history of myocardial infarction NR/NR 67.5 ± 10.6, 64.3 ± 9.8
Witham (b) et al. [17] 2013 Scotland 36/39 2 months Oral/ 100,000 IU vitamin D3 (0 and 2 month) Patients with a history of myocardial infarction NR/NR 67.5 ± 10.6, 64.3 ± 9.8
Salekzamani et al. [35] 2017 Iran 36/35 16 weeks Oral/ 50,000 IU/week for 16 weeks Patients with metabolic syndrome NR/33.37 ± 4.59 40.92 ± 5.95, 40.06 ± 4.83
Dalan et al. [10] 2016 Singapore 30/31 16 weeks Oral/ Baseline 25(OH) D ≤ 20 ng/mL: four tablets of (4000 IU/day) Baseline 25(OH)D 21–30 ng/mL: 2000 IU/day Patients with type 2 diabetes mellitus NR/28.1 ± 5.9 54.8 ± 10.8, 52.2 ± 8.2
Neyestani (a) et al. [36] 2013 Iran 50/35 12 weeks Oral/ Two 500 IU vitamin D for 12 weeks Patients with type 2 diabetes with alleles Ff No-significant/30.0 ± 5.0 52.4 ± 8.4, 52.6 ± 6.3
Neyestani (b) et al. [36] 2013 Iran 50/47 12 weeks Oral/ Two 500 IU vitamin D for 12 weeks Patients with type 2 diabetes with alleles Ff No-significant/29.0 ± 4.2 52.4 ± 8.4, 52.6 ± 6.3
Neyestani © et al. [36] 2013 Iran 50/58 12 weeks Oral/ Two 500 IU vitamin D for 12 weeks Patients with type 2 diabetes with alleles Ff No-significant/27.8 ± 4.7 52.4 ± 8.4, 52.6 ± 6.3
Sokol et al. [18] 2012 USA 45/45 12 weeks Oral/ 50,000 IU ergocalciferol per week Patients with coronary artery disease NR/30.25 ± 6.9 56.96 ± 11.6, 55 ± 9.6
Longenecker et al. [20] 2011 USA 15/29 12 weeks Oral/ Vitamin D3 4000 IU daily for 12 weeks Patients with HIV-infected overweight NR/27.5 ± 5.55 40 ± 10, 47 ± 8
Marckmann (a) et al. [37] 2012 Denmark 11/13 8 weeks Oral/ 40,000 IU vitamin D3 every week for 8 weeks Patients with chronic kidney disease NR/25.25 ± 4.77 68 ± 21.68, 71 ± 20.40
Marckmann (b) et al. [37] 2012 Denmark 13/12 8 weeks Oral/ 40,000 IU vitamin D3 every week for 8 weeks Patients with chronic kidney disease NR/25.25 ± 4.78 68 ± 21.68, 71 ± 20.40
Marckmann © et al. [37] 2012 Denmark 26/26 8 weeks Oral/ 40,000 IU vitamin D3 every week for 8 weeks Patients with chronic kidney disease NR/25.25 ± 4.79 68 ± 21.68, 71 ± 20.40
Kumar et al. [38] 2017 India 59/58 16 weeks Oral/ Cholecalciferol (300,000 IU) for 8 weeks Patients with nondiabetic chronic kidney disease stage 3–4 NR/23.51 ± 2.79 45.20 ± 11.61, 43.17 ± 11.79
Emami Naeini et al. [39] 2018 Iran 32/32 16 weeks Oral/ 50,000 IU vitamin D per week for 12 weeks End-stage renal disease patients NR/26.8 ± 7 62 ± 21, 60 ± 19
Assimon et al. [40] 2012 USA 20/20 39 weeks Oral/ 33,125 ± 17,805 IU/week for an average duration of 39.2 ± 28.3 weeks Haemodialysis patients NR/29.9 ± 6.5 64.4 ± 15.6, 68.1 ± 15.9
Zhang et al. [21] 2018 China 46/25 12 weeks Oral/ 50,000 IU cholecalciferol once a week for 12 weeks Patients with non-dialysis chronic kidney disease NR/22.7 ± 2.2 61.8 ± 16.6, 55.5 ± 14.7
Gholami et al. [41] 2016 Iran 40/20 4 weeks Intramuscular/ Single dose of 300,000 IU vitamin D3 Patients with venous thromboembolism NR/NR 53.2 ± 17.3
Borgi et al. [22] 2017 USA 41/43 8 weeks Oral/ 50,000 IU/week ergocalciferol for 4 weeks Overweight or obese adults NR/33.9 ± 5.8 35 ± 11, 39 ± 13
  1. NR, not reported